NRX Pharmaceuticals (STU:B1Q) COGS-to-Revenue : 0.00 (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is NRX Pharmaceuticals COGS-to-Revenue?

NRX Pharmaceuticals's Cost of Goods Sold for the three months ended in Jun. 2024 was €0.00 Mil. Its Revenue for the three months ended in Jun. 2024 was €0.00 Mil.

NRX Pharmaceuticals's COGS to Revenue for the three months ended in Jun. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. NRX Pharmaceuticals's Gross Margin % for the three months ended in Jun. 2024 was N/A%.

NRX Pharmaceuticals COGS-to-Revenue Historical Data

The historical data trend for NRX Pharmaceuticals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NRX Pharmaceuticals COGS-to-Revenue Chart

NRX Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

NRX Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
COGS-to-Revenue	Get a 7-Day Free Trial												-	-	-	-	-

NRX Pharmaceuticals COGS-to-Revenue Calculation

NRX Pharmaceuticals's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

NRX Pharmaceuticals's COGS to Revenue for the quarter that ended in Jun. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

NRX Pharmaceuticals (STU:B1Q) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

NRX Pharmaceuticals's Gross Margin % for the three months ended in Jun. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

NRX Pharmaceuticals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of NRX Pharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

NRX Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NRX Pharmaceuticals Inc (STU:B1Q) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

NRXP:USA

Address

1201 Orange Street, Suite 600, Wilmington, DE, USA, 19801

Website

https://nrxpharma.com

NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour.

NRX Pharmaceuticals Headlines

No Headlines